$TOVX
Theriva Biologics, Inc. Stock $tovx

$tovx Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-K Financial Statement

#000114420414019505 Filed on March 31, 2014

Income Statement

Concept	2014 Q1	2013	2012 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.120M	$4.530M	$860.0K
YoY Change	0.0%	29.06%	352.63%
% of Gross Profit
Research & Development	$2.717M	$6.507M	$11.03M
YoY Change	143.02%	-47.04%	324.23%
% of Gross Profit
Depreciation & Amortization	$3.000K	$43.00K	$10.00K
YoY Change	-72.73%	-31.75%	0.0%
% of Gross Profit
Operating Expenses	$3.839M	$12.34M	$11.89M
YoY Change	71.38%	-28.67%	326.16%
Operating Profit	-$3.839M	-$12.34M
YoY Change		-28.67%
Interest Expense	$0.00	$30.00K	$30.00K
YoY Change	-100.0%	0.0%	50.0%
% of Operating Profit
Other Income/Expense, Net	$1.000K	$21.00K	-$40.00K
YoY Change	-91.67%	40.0%	0.0%
Pretax Income	-$3.839M	-$12.34M	-$11.89M
YoY Change	71.38%	-28.67%	323.13%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$3.838M	-$12.32M	-$12.07M
YoY Change	72.26%	-27.84%	278.37%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$2.299M	-$9.477M	-$10.23M
COMMON SHARES
Basic Shares Outstanding	58.28M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q1	2013	2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.16M	$14.63M	$9.950M
YoY Change	30.99%	47.04%	48.95%
Cash & Equivalents	$11.16M	$14.63M	$9.954M
Short-Term Investments
Other Short-Term Assets	$1.332M	$1.590M	$2.509M
YoY Change	-39.18%	-36.14%	6172.5%
Inventory
Prepaid Expenses	$48.00K		$45.00K
Receivables
Other Receivables
Total Short-Term Assets	$12.49M	$16.22M	$12.46M
YoY Change	9.06%	30.18%	75.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$38.00K	$40.00K	$223.0K
YoY Change	-82.73%	-81.82%	-30.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$10.00K	$0.00	$40.00K
YoY Change	-50.0%	-100.0%	33.33%
Total Long-Term Assets	$44.00K	$40.00K	$960.0K
YoY Change	-80.87%	-95.83%	166.67%
TOTAL ASSETS
Total Short-Term Assets	$12.49M	$16.22M	$12.46M
Total Long-Term Assets	$44.00K	$40.00K	$960.0K
Total Assets	$12.53M	$16.26M	$13.42M
YoY Change	7.29%	21.16%	79.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$773.0K	$140.0K	$395.0K
YoY Change	286.5%	-65.0%	1.28%
Accrued Expenses	$0.00	$890.0K	$0.00
YoY Change			-100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$773.0K	$1.030M	$395.0K
YoY Change	286.5%	157.5%	-5.95%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$773.0K	$1.030M	$395.0K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$773.0K	$1.030M	$395.0K
YoY Change	286.5%	157.5%	-5.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$85.10M		-$68.94M
YoY Change
Common Stock	$96.85M		$81.97M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.76M	$15.23M	$13.03M
YoY Change
Total Liabilities & Shareholders Equity	$12.53M	$16.26M	$13.42M
YoY Change	7.29%	21.16%	79.45%

Cashflow Statement

Concept	2014 Q1	2013	2012 Q4
OPERATING ACTIVITIES
Net Income	-$3.838M	-$12.32M	-$12.07M
YoY Change	72.26%	-27.84%	278.37%
Depreciation, Depletion And Amortization	$3.000K	$43.00K	$10.00K
YoY Change	-72.73%	-31.75%	0.0%
Cash From Operating Activities	-$3.470M	-$7.719M	-$4.780M
YoY Change	109.04%	-13.43%	545.95%
INVESTING ACTIVITIES
Capital Expenditures	$4.000K	$36.00K	$0.00
YoY Change	33.33%	260.0%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$4.000K	-$36.00K	$0.00
YoY Change		260.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$13.22M
YoY Change		22.44%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$4.000K	$12.43M	10.15M
YoY Change	-98.26%	1.84%	101400.0%
NET CHANGE
Cash From Operating Activities	-$3.470M	-$7.719M	-4.780M
Cash From Investing Activities	-$4.000K	-$36.00K	0.000
Cash From Financing Activities	$4.000K	$12.43M	10.15M
Net Change In Cash	-$3.470M	$4.671M	5.370M
YoY Change	142.66%	42.58%	160.68%
FREE CASH FLOW
Cash From Operating Activities	-$3.470M	-$7.719M	-$4.780M
Capital Expenditures	$4.000K	$36.00K	$0.00
Free Cash Flow	-$3.474M	-$7.755M	-$4.780M
YoY Change	108.9%	-13.12%	545.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Assets Assets	16257000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	142000	USD
CY2013Q4	syn	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	4000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	395000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	1027000	USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9954000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14625000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2509000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1591000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	12463000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	16216000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	223000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	37000	USD
CY2012Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	700000	USD
CY2013Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	0	USD
CY2012Q4	syn	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	37000	USD
CY2012Q4	us-gaap	Assets Assets	13423000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	395000	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	44000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	58000	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	81925000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	96430000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-68941000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-81258000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	13028000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	15230000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13423000	USD
CY2012Q4	syn	Prepaid Expenses Research And Development PrepaidExpensesResearchAndDevelopment	2412000	USD
CY2013Q4	syn	Prepaid Expenses Research And Development PrepaidExpensesResearchAndDevelopment	1361000	USD
CY2012Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	17000	USD
CY2013Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	0	USD
CY2012Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	45000	USD
CY2013Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	53000	USD
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2509000	USD
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1591000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	465000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	56000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	242000	USD
CY2012	syn	Share Based Compensation Arrangement By Share Based Payment Award Options Expected Forfeiture Rate In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod	0	pure
CY2013	syn	Share Based Compensation Arrangement By Share Based Payment Award Options Expected Forfeiture Rate In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod	0	pure
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44444230	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58295808	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44362748	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58214326	shares
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5012000	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5832000	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12287000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6507000	USD
CY2012	us-gaap	Operating Expenses OperatingExpenses	17299000	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	12339000	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17299000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12339000	USD
CY2012	us-gaap	Investment Income Interest InvestmentIncomeInterest	33000	USD
CY2013	us-gaap	Investment Income Interest InvestmentIncomeInterest	33000	USD
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-18000	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12000	USD
CY2012	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	15000	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	21000	USD
CY2012	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-17284000	USD
CY2013	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-12318000	USD
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	216000	USD
CY2013	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-17068000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-12317000	USD
CY2012	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.50
CY2013	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.27
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.01
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	36000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-36000	USD
CY2012	syn	Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises	2082000	USD
CY2013	syn	Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises	232000	USD
CY2013	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.49
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34896592	shares
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	45667813	shares
CY2012	us-gaap	Profit Loss ProfitLoss	-17068000	USD
CY2013	us-gaap	Profit Loss ProfitLoss	-12318000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	1851000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	1669000	USD
CY2012	us-gaap	Depreciation Depreciation	63000	USD
CY2013	us-gaap	Depreciation Depreciation	43000	USD
CY2012	syn	Provision For Uncollectible Accounts Receivable ProvisionForUncollectibleAccountsReceivable	442000	USD
CY2013	syn	Provision For Uncollectible Accounts Receivable ProvisionForUncollectibleAccountsReceivable	0	USD
CY2012	syn	Provision For Uncollectible Note And Interest Receivables ProvisionForUncollectibleNoteAndInterestReceivables	0	USD
CY2013	syn	Provision For Uncollectible Note And Interest Receivables ProvisionForUncollectibleNoteAndInterestReceivables	763000	USD
CY2012	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2013	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-58000	USD
CY2012	syn	Equipment Impairment Loss EquipmentImpairmentLoss	47000	USD
CY2013	syn	Equipment Impairment Loss EquipmentImpairmentLoss	121000	USD
CY2012	syn	Gain Loss On Sale Of Discontinued Operation GainLossOnSaleOfDiscontinuedOperation	677000	USD
CY2013	syn	Gain Loss On Sale Of Discontinued Operation GainLossOnSaleOfDiscontinuedOperation	0	USD
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-14000	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2544000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-855000	USD
CY2012	syn	Increase Decrease In Deposits And Other Assets IncreaseDecreaseInDepositsAndOtherAssets	6000	USD
CY2013	syn	Increase Decrease In Deposits And Other Assets IncreaseDecreaseInDepositsAndOtherAssets	-33000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-253000	USD
CY2012	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-29000	USD
CY2013	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	885000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8916000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7719000	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12202000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12426000	USD
CY2012	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	3276000	USD
CY2013	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	4671000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6678000	USD
CY2012	us-gaap	Interest Paid InterestPaid	0	USD
CY2013	us-gaap	Interest Paid InterestPaid	0	USD
CY2012	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2013	dei	Document Type DocumentType	10-K
CY2013	dei	Amendment Flag AmendmentFlag	false
CY2013	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
CY2013	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013	syn	Stock Issued For Acquisitions Of Program Assets StockIssuedForAcquisitionsOfProgramAssets	0	USD
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7059000	USD
CY2012	syn	Stock Issued For License Agreement StockIssuedForLicenseAgreement	0	USD
CY2013	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2013	dei	Trading Symbol TradingSymbol	SYN
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	58276556	shares
CY2013	dei	Entity Registrant Name EntityRegistrantName	Synthetic Biologics, Inc.
CY2013	dei	Entity Central Index Key EntityCentralIndexKey	0000894158
CY2013	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q2	dei	Entity Public Float EntityPublicFloat	47100000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	0	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	885000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	395000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1027000	USD
CY2013	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1000	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1852000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1669000	USD
CY2012	syn	Stock Issued During Period Value For Exclusive Channel Collaboration Agreement StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement	7814000	USD
CY2012	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1169000	USD
CY2012	syn	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	2082000	USD
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10120000	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	12193000	USD
CY2012Q4	us-gaap	Minority Interest MinorityInterest	0	USD
CY2013Q4	us-gaap	Minority Interest MinorityInterest	0	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13028000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15230000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	232000	USD
CY2013	syn	Stock Issued During Period Value License Agreement StockIssuedDuringPeriodValueLicenseAgreement	425000	USD
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10120000	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12193000	USD
CY2012	syn	Issue Of Stock For Exclusive Channel Collaboration Agreement IssueOfStockForExclusiveChannelCollaborationAgreement	-7815000	USD
CY2013	syn	Issue Of Stock For Exclusive Channel Collaboration Agreement IssueOfStockForExclusiveChannelCollaborationAgreement	0	USD
CY2012	syn	Stock Issued For Acquisitions Of Program Assets StockIssuedForAcquisitionsOfProgramAssets	-1169000	USD
CY2013	syn	Stock Issued For License Agreement StockIssuedForLicenseAgreement	-425000	USD
CY2012	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	680000	USD
CY2013	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1031000	USD
CY2012	syn	Stock Issuance Cost StockIssuanceCost	680000	USD
CY2013	syn	Stock Issuance Cost StockIssuanceCost	1031000	USD
CY2012Q4	us-gaap	Prepaid Insurance PrepaidInsurance	35000	USD
CY2013Q4	us-gaap	Prepaid Insurance PrepaidInsurance	177000	USD
CY2012Q4	syn	Accrued Vendor Payments AccruedVendorPayments	0	USD
CY2013Q4	syn	Accrued Vendor Payments AccruedVendorPayments	220000	USD
CY2012Q4	syn	Accrued Compensation AccruedCompensation	0	USD
CY2013Q4	syn	Accrued Compensation AccruedCompensation	3000	USD
CY2012	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	2900000	USD
CY2009	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1000000	USD
CY2009Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	5
CY2013Q4	us-gaap	Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased	81482	shares
CY2013	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	50000	USD
CY2013Q4	us-gaap	Preferred Stock Redemption Price Per Share PreferredStockRedemptionPricePerShare	0.61
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b><i>Use of Estimates</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.A. requires management to make estimates and assumptions that affect the reported amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the estimated useful lives for property and equipment, fair value of warrants and stock options granted for services or compensation, respectively, estimates of the probability and potential magnitude of contingent liabilities, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2012	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-5803000	USD
CY2013	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-4188000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12058000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21067000	USD
CY2012Q4	syn	Deferred Tax Assets Stocks Issued For Services DeferredTaxAssetsStocksIssuedForServices	318000	USD
CY2013Q4	syn	Deferred Tax Assets Stocks Issued For Services DeferredTaxAssetsStocksIssuedForServices	441000	USD
CY2012	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-676000	USD
CY2013	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-488000	USD
CY2012	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	5000	USD
CY2013	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	6000	USD
CY2012	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	518000	USD
CY2013	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	511000	USD
CY2012	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-5956000	USD
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-4159000	USD
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2012	syn	Realized Loss On Debt Securities RealizedLossOnDebtSecurities	0	USD
CY2013	syn	Realized Loss On Debt Securities RealizedLossOnDebtSecurities	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16168000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16908000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21067000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16908000	USD
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	127000	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	231000	USD
CY2012Q4	syn	Deferred Tax Assets Bad Debts DeferredTaxAssetsBadDebts	1099000	USD
CY2013Q4	syn	Deferred Tax Assets Bad Debts DeferredTaxAssetsBadDebts	1099000	USD
CY2012Q4	syn	Deferred Tax Assets Stock Issued For Acquisition Of Program DeferredTaxAssetsStockIssuedForAcquisitionOfProgram	444000	USD
CY2013Q4	syn	Deferred Tax Assets Stock Issued For Acquisition Of Program DeferredTaxAssetsStockIssuedForAcquisitionOfProgram	652000	USD
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0396	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0396	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.3796	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.3796	pure
CY2013Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	42800000	USD
CY2010	syn	Additional Milestone Payments AdditionalMilestonePayments	5000000	USD
CY2010	syn	Royalty Revenue Percentage RoyaltyRevenuePercentage	0.07	pure
CY2010	syn	Marketing Approval MarketingApproval	10000000	USD
CY2012	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	47000	USD
CY2013	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	121000	USD
CY2013Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.8	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2013Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1600000	USD
CY2013Q4	us-gaap	Minority Interest Ownership Percentage By Parent MinorityInterestOwnershipPercentageByParent	0.2	pure
CY2013Q4	us-gaap	Other Commitment Due In Next Twelve Months OtherCommitmentDueInNextTwelveMonths	378000	USD
CY2013Q4	us-gaap	Other Commitment Due In Second Year OtherCommitmentDueInSecondYear	336000	USD
CY2013Q4	us-gaap	Other Commitment Due In Third Year OtherCommitmentDueInThirdYear	10000	USD
CY2013Q4	us-gaap	Other Commitment Due In Fourth Year OtherCommitmentDueInFourthYear	10000	USD
CY2013Q4	us-gaap	Other Commitment Due In Fifth Year OtherCommitmentDueInFifthYear	10000	USD
CY2013Q4	us-gaap	Other Commitment Due In Fourth And Fifth Year OtherCommitmentDueInFourthAndFifthYear	744000	USD
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	2.27
CY2009	us-gaap	Line Of Credit Facility Periodic Payment LineOfCreditFacilityPeriodicPayment	197000	USD
CY2009	us-gaap	Line Of Credit Facility Periodic Payment Interest LineOfCreditFacilityPeriodicPaymentInterest	5000	USD
CY2013Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.17
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P1Y3M18D
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	985855	shares
CY2012	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	123000	USD
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	68000	USD
CY2012	us-gaap	Registration Payment Arrangement Term RegistrationPaymentArrangementTerm	In connection with the transactions contemplated by the Stock Purchase Agreement, and pursuant to the Registration Rights Agreement executed and delivered by the Company to Intrexon, the Company agreed to file a resale registration statement registering the resale of the First Tranche Shares within 120 days of the closing date of such issuance.
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	1.14
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	2.20
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.74	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.1	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0071	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0026	pure
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y
CY2012Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1561869	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	222500	shares
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	883882	shares
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	144444	shares
CY2013Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	756043	shares
CY2012Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.11
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.69
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.93
CY2012	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod	1768167	shares
CY2013	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod	0	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	844373	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0	shares
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.95
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.99
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1632501	shares
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	3259186	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1632501	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.71
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2012	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue	1.11
CY2013	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue	0
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	3.32
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.99
CY2012	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	127000	USD
CY2013	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	231000	USD
CY2012	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	87000	USD
CY2013	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	1000000	USD
CY2013	syn	Operating Loss Carryforwards Expire Date OperatingLossCarryforwardsExpireDate	2033
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2013	syn	Stock Issued Of During Period Value New Issues StockIssuedOfDuringPeriodValueNewIssues	1000	USD
CY2013	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	1000	USD
CY2012	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
CY2013Q4	syn	Accrued Manufacturing Costs AccruedManufacturingCosts	-662000	USD
CY2012Q4	syn	Accrued Manufacturing Costs AccruedManufacturingCosts	0	USD
CY2013Q4	syn	Exchange Percentage Of Unregistered Common Stock ExchangePercentageOfUnregisteredCommonStock	0.5	pure
CY2013	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	3000000	USD
CY2013Q4	syn	Deferred Tax Assets Stock Issued Forlicense Agreement DeferredTaxAssetsStockIssuedForlicenseAgreement	2707000	USD
CY2012Q4	syn	Deferred Tax Assets Stock Issued Forlicense Agreement DeferredTaxAssetsStockIssuedForlicenseAgreement	2989000	USD

Files In Submission

Name	View Source	Status
0001144204-14-019505-index-headers.html	Edgar Link	pending
0001144204-14-019505-index.html	Edgar Link	pending
0001144204-14-019505.txt	Edgar Link	pending
0001144204-14-019505-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
syn-20131231.xml	Edgar Link	completed
syn-20131231.xsd	Edgar Link	pending
syn-20131231_cal.xml	Edgar Link	unprocessable
syn-20131231_def.xml	Edgar Link	unprocessable
syn-20131231_lab.xml	Edgar Link	unprocessable
syn-20131231_pre.xml	Edgar Link	unprocessable
tchart.jpg	Edgar Link	pending
tchart1.jpg	Edgar Link	pending
tlogo.jpg	Edgar Link	pending
v372138_10k.htm	Edgar Link	pending
v372138_ex10-49.htm	Edgar Link	pending
v372138_ex21.htm	Edgar Link	pending
v372138_ex23-1.htm	Edgar Link	pending
v372138_ex31-1.htm	Edgar Link	pending
v372138_ex31-2.htm	Edgar Link	pending
v372138_ex32-1.htm	Edgar Link	pending
v372138_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TOVX
Theriva Biologics, Inc. Stock $tovx

2014 Q1 Form 10-K Financial Statement

#000114420414019505 Filed on March 31, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TOVX Theriva Biologics, Inc. Stock $tovx

2014 Q1 Form 10-K Financial Statement

#000114420414019505 Filed on March 31, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TOVX
Theriva Biologics, Inc. Stock $tovx